PMC5016206_01
Antiretroviral regimens, serum creatinine, and cystatin-C prior to and after initiating a salvage regimen with tenofovir alafenamide. COBI = cobicistat, DRV/r = ritonavir-boosted darunavir, DTG = dolutegravir, EVG = elvitegravir, FTC = emtricitabine, RAL = raltegravir, SCr = serum creatinine, TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate, T20 = enfuvirtide
nihms-767632-f0001.jpg
PMC5016206_01_nihms-767632-f0001.jpg
F1
In October 2013, two months after starting a regimen consisting of enfuvirtide and elvitegravir/cobicistat/TDF/emtricitabine (Figure 1), his serum creatinine increased from 1.47 mg/dL (130 mumol/L) to 4.55 mg/dL (402 mumol/L).
Antiretroviral regimens, HIV viral load, and CD4+ cell count prior to and after initiating a salvage regimen with tenofovir alafenamide. COBI = cobicistat, DRV/r = ritonavir-boosted darunavir, DTG = dolutegravir, EVG = elvitegravir, FTC = emtricitabine, RAL = raltegravir, TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate, T20 = enfuvirtide
nihms-767632-f0002.jpg
PMC5016206_01_nihms-767632-f0002.jpg
F2
On 1 July, 2014, after discontinuation of TDF and while on a regimen of only raltegravir and emtricitabine, his SCr decreased to 1.49 mg/dL (132 mumol/L, eGFR 52 mL/min/1.73 m2) and his viral load increased by 0.57 log10 to 39,950 copies/mL (Figure 2), suggesting that TDF was responsible for partial viral suppression.